{
    "ticker": "VCRB",
    "name": "Vaccinex, Inc.",
    "description": "Vaccinex, Inc. is a clinical-stage biotechnology company focused on developing innovative therapeutic monoclonal antibodies for the treatment of cancer and neurodegenerative diseases. Founded in 2000, Vaccinex has dedicated itself to harnessing the power of its proprietary technology platform, which enables the identification and development of antibodies that target specific disease mechanisms. The company's lead product candidate, VX15/2503, is designed to inhibit the activity of the semaphorin 4D (Sema4D) pathway, which is implicated in various cancers and neurological disorders. With a robust pipeline, Vaccinex aims to address significant unmet medical needs by advancing therapies that can improve patient outcomes. The company is also actively involved in research collaborations and partnerships to expand its therapeutic offerings and accelerate the development of its candidates. Through its commitment to scientific excellence and innovation, Vaccinex strives to contribute to the advancement of personalized medicine and enhance the quality of life for patients suffering from debilitating conditions.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Rochester, New York, USA",
    "founded": "2000",
    "website": "https://www.vaccinex.com",
    "ceo": "Maurice Zauderer",
    "social_media": {
        "twitter": "https://twitter.com/VaccinexInc",
        "linkedin": "https://www.linkedin.com/company/vaccinex"
    },
    "investor_relations": "https://www.vaccinex.com/investor-relations",
    "key_executives": [
        {
            "name": "Maurice Zauderer",
            "position": "CEO"
        },
        {
            "name": "Ying Chen",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Oncology",
            "products": [
                "VX15/2503"
            ]
        },
        {
            "category": "Neurodegenerative Diseases",
            "products": [
                "VX15/2503"
            ]
        }
    ],
    "seo": {
        "meta_title": "Vaccinex, Inc. | Innovative Biotherapeutics for Cancer and Neurological Diseases",
        "meta_description": "Explore Vaccinex, Inc., a clinical-stage biotechnology company developing monoclonal antibodies for cancer and neurodegenerative diseases. Learn about our innovative therapies and commitment to patient care.",
        "keywords": [
            "Vaccinex",
            "Biotechnology",
            "Monoclonal Antibodies",
            "Cancer Treatment",
            "Neurological Diseases",
            "VX15/2503"
        ]
    },
    "faq": [
        {
            "question": "What does Vaccinex specialize in?",
            "answer": "Vaccinex specializes in developing therapeutic monoclonal antibodies for cancer and neurodegenerative diseases."
        },
        {
            "question": "Who is the CEO of Vaccinex?",
            "answer": "Maurice Zauderer is the CEO of Vaccinex, Inc."
        },
        {
            "question": "Where is Vaccinex headquartered?",
            "answer": "Vaccinex is headquartered in Rochester, New York, USA."
        },
        {
            "question": "What is Vaccinex's lead product candidate?",
            "answer": "The lead product candidate of Vaccinex is VX15/2503, targeting the semaphorin 4D pathway."
        },
        {
            "question": "When was Vaccinex founded?",
            "answer": "Vaccinex was founded in 2000."
        }
    ],
    "competitors": [
        "REGN",
        "BMY",
        "AMGN",
        "EXEL"
    ],
    "related_stocks": [
        "NVAX",
        "MRNA",
        "PFE",
        "GILD"
    ]
}